Search Results - "Scholl, S.M."

Age as prognostic factor in premenopausal breast carcinoma by de la Rochefordiere, A, Asselain, B, Campana, F, Scholl, S M, Fenton, J, Vilcoq, J R, Durand, J C, Pouillart, P, Magdelenat, H, Fourquet, A

“…Whether or not young age at diagnosis is an adverse prognostic factor in breast cancer has long been controversial, in part because much previous work has not…”
Get more information

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6 by Scholl, S M, Fourquet, A, Asselain, B, Pierga, J Y, Vilcoq, J R, Durand, J C, Dorval, T, Palangié, T, Jouve, M, Beuzeboc, P

“…The aim of this study was to assess a potential advantage in survival by neoadjuvant as compared to adjuvant chemotherapy. 414 premenopausal patients with…”
Get more information

Breast tumour response to primary chemotherapy predicts local and distant control as well as survival by Scholl, S.M., Pierga, J.Y., Asselain, B., Beuzeboc, P., Dorval, T., Garcia-Giralt, E., Jouve, M., Palangié, T., Remvikos, Y., Durand, J.C., Fourquet, A., Pouillart, P.

“…The purpose of the present paper was to evaluate correlations between clinical response to chemotherapy and outcome in a subgroup analysis of premenopausal…”
Get full text

Control and manipulation of malignant tumour spread: Second institut curie oncology conference 5–8 June, 1996 by Scholl, S.M.

Get full text

The immune response to breast cancer by Scholl, S.M., Baron, C., Salamaro, J., Beuzeboc, P., Deneux, L., Beuvon, F., Pouillart, P.

Get full text

Neoadjuvant chemotherapy in operable breast cancer by Scholl, S M, Asselain, B, Palangie, T, Dorval, T, Jouve, M, Garcia Giralt, E, Vilcoq, J, Durand, J C, Pouillart, P

“…Primary chemotherapy in localised breast cancer may prevent tumour spread during surgical treatment and reduce proliferation of micrometastases. A randomised…”
Get more information

Two distinct cell populations are obtained from human blood monocytes cultured with M-CSF, GM-CSF and IL-4 by Baron, C.L, Scholl, S.M, Bausinger, H, Hanau, D, Pouillart, P, Goud, B, Salamero, J

Get full text

Phase II Trial of Doxorubicin, 5-Fluorouracil, Etoposide, and Cisplatin in Advanced or Recurrent Endometrial Carcinoma by Pierga, J-Y., Diéras, V., Beuzeboc, P., Dorval, T., Palangié, T., Jouve, M., Scholl, S.M., Garcia-Giralt, E., Pouillart, P.

“…We have previously reported an overall response rate of 41% and a median survival duration of 14 months in a series of 49 patients with metastatic or recurrent…”
Get full text

Treatment of Advanced or Recurrent Endometrial Carcinoma with Combination of Etoposide, Cisplatin, and 5-Fluorouracil: A Phase II Study by Pierga, J-Y., Dieras, V., Paraiso, D., Dorval, T., Palangie, T., Beuzeboc, P., Jouve, M., Scholl, S.M., Garcia-Giralt, E., Pouillart, P.

“…Forty-nine consecutive patients with metastatic or recurrent endometrial carcinoma were treated with a monthly combination chemotherapy consisting of VP 16-213…”
Get full text